Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity

Cited by (457)

Items 301–400 of 457

1. GNB4 Silencing Promotes Pyroptosis to Inhibit the Development of Glioma by Activating cGAS–STING Pathway
   Zhiqiang Gao, Jing Yang · 2024 · Molecular Biotechnology
2. Cytosolic bacterial pathogens activate TLR pathways in tumors that synergistically enhance STING agonist cancer therapies
   Meggie Danielson, Christopher J. Nicolai, Thaomy T Vo, Natalie K. Wolf, Thomas Burke · 2024 · iScience
3. Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumors
   Sven Borchmann, Carolin Selenz, Mia Lohmann, Hanna Ludwig, Asmae Gassa, Johannes Brägelmann, Philipp Lohneis, Lydia Meder, Julia Mattlener, Sara Breid et al. · 2022 · Journal for ImmunoTherapy of Cancer
4. DAGM: A novel modelling framework to assess the risk of HER2-negative breast cancer based on germline rare coding mutations
   Mei Yang, Yanhui Fan, Zhiyong Wu, Jin Gu, Zhendong Feng, Qiangzu Zhang, Shunhua Han, Zhonghai Zhang, Xu Li, Yi-Ching Hsueh et al. · 2021 · EBioMedicine
5. Bis-2′-F-cGSASMP isomers encapsulated in cytidinyl/cationic lipids act as potent in situ autologous tumor vaccines
   Jing Yu, Xiaotong Yu, Xudong Sun, Quanxin Wang, Sijie Long, Runan Ren, Zhu Guan, Zhenjun Yang · 2024 · Molecular Therapy
6. Intradermal vaccination with a phytoglycogen nanoparticle and STING agonist induces cytotoxic T lymphocyte-mediated antitumor immunity
   Juan F. Hernandez-Franco, Imran M. Jan, Bennett D. Elzey, Harm HogenEsch · 2024 · npj Vaccines
7. Leveraging innate immune signals in CD8+ T cells to boost antitumor immunity
   Gabriella K. Albert, Phoebe Cao, Eduardo Davila · 2025 · Frontiers in Immunology
8. Exploring novel strategies of oncolytic viruses and gut microbiota to enhance CAR-T cell therapy for colorectal cancer
   Jia Yi, Sangmu Quji, Luxuan Guo, Zhongqiu Chai, Xianbin Kong, Jingyan Meng · 2025 · Cellular Immunology
9. “Emerging precision drug delivery systems for controlled activation of the cGAS–STING pathway in Cancer, infection, and autoimmune disorders”
   Gajjala Pavani, Gurubasavaraja Swamy Purawarga Matada, Abhishek Ghara, Arghya Paik, Anubhav Richard David, Changala Kavyasree · 2025 · International Immunopharmacology
10. STING Ablation in T Cells Is Required for the Efficacy of STING Agonists in CAR-T Cell Immunotherapy of Pancreatic Cancer
    Ignazio Piseddu, Rebekka Endres, Fabian Lanzl, Linda Hammann, Marleen Bérouti, Matthias B. Thaler, Lisa Fahr, Hannah Fischer, Varvara Varlamova, Jan Gärtig et al. · 2026 · Gastroenterology
11. Harnessing cGAS – STING axis for therapeutic benefits in systemic lupus erythematosus
    Liu Chang · 2024 · International Journal of Rheumatic Diseases
12. Assembly of 2′,3′-Cyclic guanosine Monophosphate-Adenosine monophosphate and their spontaneous intracellular disassembly for enhanced antitumor immunity via natural STING pathway activation
    Jung Yeon Park, Miso Kang, Songhyun Lim, Hyejin Cho, Seoyeong Yang, Soo Yeon Baek, Linfeng Tan, Chiman Song, Myongsoo Lee, Bongjun Yeom et al. · 2024 · Chemical Engineering Journal
13. Au naturale: use of biologically derived cyclic di-nucleotides for cancer immunotherapy
    Christopher M. Waters · 2021 · Open Biology
14. A Therapeutic Vaccine in Combination with Cyclic GMP–AMP Cures More Differentiated Melanomas in Mice
    Md Masud Alam, Timothy Gower, Mengmeng Jiang, Joost J. Oppenheim, De Yang · 2023 · The Journal of Immunology
15. Discovery of novel amidobenzimidazole derivatives as orally available small molecule modulators of stimulator of interferon genes for cancer immunotherapy
    Min Jae Jeon, Hyelim Lee, Seongman Jo, Miso Kang, Jeong Hyun Jeong, So Hyeon Jeong, Joo‐Youn Lee, Gyu Yong Song, Hyunah Choo, Sanghee Lee et al. · 2023 · European Journal of Medicinal Chemistry
16. Sonoporation‐Enhanced Delivery of STING Agonist Induced Robust Immune Modulation and Tumor Regression
    Jun Xu, Nicolas Solban, Yun Wang, Heidi M. Ferguson, Samanthi A. Perera, Ken Yu Lin, Mingmei Cai, Paul L. Miller, Ernest G. Schutt, Clayton T. Larsen et al. · 2021 · Advanced Therapeutics
17. An Immune Nanoenhancer Revitalizes Chemotherapeutics to Tailor Tumor‐Derived dsDNA for Anticancer Immunoengineering
    Ying Liu, Yachao Li, Wensheng Gong, Dongzhe Zou, Beiling Guo, Zenan Zeng, Xiaoxiao Li, Yini Xu, Xianghui Xu · 2025 · Advanced Materials
18. 18F-Labeled Amidobenzimidazole Analogue for Visualizing STING Expression in Tumor
    Jianyang Fang, Jingru Zhang, Lingxin Meng, Huifeng Li, Dongsheng Xia, Yaoxuan Wang, Hao Chen, Zhenhuan Liao, Rongqiang Zhuang, Yesen Li et al. · 2024 · Molecular Pharmaceutics
19. The cyclic guanosine monophosphate synthase-stimulator of interferon genes pathway as a potential target for tumor immunotherapy
    Rui Chen, Mingxia Liu, Quanhong Jiang, Xiangbo Meng, Junmin Wei · 2023 · Frontiers in Immunology
20. A novel STING agonist with systemic and durable anti‐tumour activity
    Xiyuan Wang, Ancheng Shen, Yan Zhang, Xiaoxu Chen, Jian Ding, Ao Zhang, Meiyu Geng, Chunyong Ding, Zuoquan Xie · 2023 · Clinical and Translational Discovery
21. Putting the sting back in STING therapy: novel delivery vehicles for improved STING activation
    Sina Khorsandi, Kristin Michelle Huntoon, Jacques Lux · 2024 · Frontiers in Chemical Biology
22. Insight into the dichotomous regulation of STING activation in immunotherapy
    Zhaoxue Hu, Yifei K. Yang, Lincheng Fang, Jinpei Zhou, Huibin Zhang · 2021 · Immunopharmacology and Immunotoxicology
23. Checkpoint Kinase 1 (Chk1) inhibition fails to activate the Stimulator of Interferon Genes (STING) innate immune signalling in a human coculture cancer system
    Teresa Brooks, Joanne Wayne, Andrew J. Massey · 2021 · Molecular Biomedicine
24. Reproductive safety of STING agonists MSA-2 and manganese-MSA-2
    Ya Cai, Tian He, Tao Yang, Yating Li, Lirong Yi, Wenqing Li, Peng Zhou · 2024 · Toxicology Research
25. Advancing cancer immunotherapy through emerging intratumoral delivery and biomedical imaging technologies
    Eun-Seo Choi, Alexander F. Bagley, Sakib Haque, Celeste Winters, Conroy Sun · 2024 · Materials Today Advances
26. The human STING agonist E7766 induces immunogenic tumor clearance, independent of tumor-intrinsic STING expression in the KRAS G12D/+ Trp53 −/− murine model of sarcoma
    Karys M. Hildebrand, Kurt Hildebrand, Carolina Salazar Arcila, Kayla Marritt, Jahanara Rajwani, Golpira Elmi Assadzadeh, Antoine Dufour, Frank Robert Jirik, Michael J. Monument · 2025 · OncoImmunology
27. Advances in STING Pathway Modulation for Cancer and Immunotherapy: A Comprehensive Review of Preclinical and Clinical Studies (2020–2024)
    Rahaman Shaik, Komal Suthar, Chandrika Balija, Shifa Aleem, Fatima Sarwar Syeda, Sana Syeda, Shireen Begum · 2025 · Cancer Biotherapy and Radiopharmaceuticals
28. Systematic discovery of pathogen effector functions across human pathogens and pathways
    Tomás Pachano, He Leng, Guillaume Dugied, Travis Tribble, Vincent Loubière, Yeojin Lee, Felix Rauh, Victor Manon, Kevin Yuan, Jocelyn Nurtanto et al. · 2026 · Cell
29. MnUA–DOX–artesunate hydrogel remodels immunosuppressive tumor microenvironment and prevents postoperative recurrence in triple-negative breast cancer
    Keneng Cai, Rui Xia, Mengyao Xu, Wanying Chen, Wenli Cai, Xinyu Liu, Tiantian Guo, Weichi Jiang, Chuyi Yu, Jianjia Feng et al. · 2026 · Journal of Nanobiotechnology
30. STING agonist-primed supramolecular oncolytic hydrogel vaccine for tuning tumors against themselves
    Mingmei Guo, Shuyi Xie, Chenwei Jiang, Minglu Tang, Wen Zhang, Lin Xiong, Qi Shang, Xiaoran An, Feihu Wang · 2026 · Journal of Controlled Release
31. Therapeutic targeting of the cGAS-STING pathway in human disease
    Akanksha S. Mahajan, Connor M. Forsyth, Cao Dai Phung, Xinhe Shen, Rachel Jarvis, Alexander H. Stegh · 2026 · Journal of Clinical Investigation
32. Recent advances in nanoadjuvant-triggered STING activation for enhanced cancer immunotherapy
    Zicong Xu, Yi-Hong Wu, Junjie Hu, Zhaozhao Mei, Yutong Zhao, Keda Yang, Yi Shi, Xiaoling Xu · 2024 · Heliyon
33. 5′-Phosphorothioester Linked Cyclic Dinucleotides, Endo-S-CDNs, Displaying Impressive Antitumor Activities In Vivo when Dosed Subcutaneously
    Simpa K. Yeboah, Sagarika Meher, Haley Anne Harper, Carli J. McMahan, Bennett D. Elzey, Herman O. Sintim · 2025 · ACS Bio & Med Chem Au
34. Beyond interferons: Non-canonical roles of MITA/STING
    Liting Zhang, Chuchu Zhang, Junjie Zhang · 2025 · Cell Insight
35. Single-cell transcriptome analysis profiles the expression features of TMEM173 in BM cells of high-risk B-cell acute lymphoblastic leukemia
    Yiqing Cai, Xiaomin Chen, Tiange Lu, Zhuoya Yu, Shunfeng Hu, Jiarui Liu, Xiangxiang Zhou, Xin Wang · 2023 · BMC Cancer
36. Targeted immune activation in pediatric solid tumors: opportunities to complement local control approaches
    Emily P. Vonderhaar, Michael B. Dwinell, Brian T. Craig · 2023 · Frontiers in Immunology
37. Unveiling cGAS mechanisms: Insights into DNA damage and immune sensing in cancer
    Min-Guk Cho, Gaorav P. Gupta · 2025 · DNA repair
38. Identification of (−)-Epigallocateshin gallate derivatives promoting innate immune activation via 2′,3′-cyclic GMP-AMP-stimulator of interferon genes pathway
    Hyelim Lee, Jeong Hyun Jeong, Taegum Lee, Youhoon Chong, Hyunah Choo, Sanghee Lee · 2023 · Bioorganic & Medicinal Chemistry Letters
39. A clinically-relevant STING agonist restrains human TH17 cell inflammatory profile
    Luis Eduardo Alves Damasceno, Thiago M. Cunha, Fernando Q. Cunha, Tim D. Sparwasser, José Carlos Alves-Filho · 2023 · International Immunopharmacology
40. Conjugated STING-agonist nanoparticles enhance antitumor immunity in multiple tumor models
    Pere Dosta, Alexander M. Cryer, Michelle Z. Dion, Tsubasa Shiraishi, Steven Langston, David P. P. Lok, Jianing Wang, Sean Harrison, Shiran Ferber, Santhosh Kalash Rajendrakumar et al. · 2022 · Research Square
41. Enhancing Tumor-Specific immunity with SLdacA: A attenuated Salmonella-mediated c-di-AMP delivery system targeting the STING pathway
    Yuanjia Huang, Linghua Piao, Xiande Liu · 2024 · International Journal of Pharmaceutics
42. Combination strategies with STING agonists: Current advances and future directions
    Kun Sun, Xuanyu Fu, Yuying Man, Fangzhou Liu, Zhipeng Qu, Yuanying Ou, Wenqi Cheng, Jinlei Bian, Zhiyu Li, Jubo Wang et al. · 2025 · European Journal of Pharmacology
43. Laryngeal squamous cell carcinoma: a functional “two-hit” model of papillomavirus–Epstein–Barr virus synergistic carcinogenesis
    Fang Wang, Hui Huangfu · 2026 · Frontiers in Cellular and Infection Microbiology
44. Bispecific Macrophage Nano-Engager Couples Dual Checkpoint Blockade with Stimulator of Interferon Genes Activation to Potentiate Antitumor Immunity
    Bao-Toan Nguyen Dang, Khang‐Yen Pham, Huyen Thi Thu Le, Thoa Thi Kim Nguyen, An Thi Thanh Vu, Anil Giri, Prabhat Shrestha, Taeg Kyu Kwon, Jee‐Heon Jeong, Simmyung Yook · 2026 · ACS Nano
45. Intratumoral T cell activation kills tumors regardless of T cell specificity
    Olivia C. Ghirardelli Smith, Tyler T. Dao, Noah Veis Gavil, Stephen D. O’Flanagan, Adam J. Rubin, Son Nguyen, Matthew Watowich, Nuo Liu, Eyob Weyu, Clare F. Quarnstrom et al. · 2026 · Nature Immunology
46. PARP inhibitor-induced anti-tumour chemokine response is suppressed by dipeptidyl peptidase 4 (DPP4) in ovarian cancer
    Christoph Stange, Tobias F. Dreyer, Maximilian Riedel, Franziska A. V. Elsen, Stefanie Seitz, Dorine Hamann, Marion B. Kiechle, Holger Bronger · 2025 · British Journal of Cancer
47. Nanocarrier-enabled STING agonist delivery for enhanced cancer immunotherapy
    Yuxiang Wu, Qi Liu · 2025 · Journal of Materials Chemistry B
48. Microtubule-destabilizing agents enhance STING-mediated innate immune response via biased mechanism in human monocyte cells
    Songhyun Lim, Hee Ra Jung, Hyelim Lee, Yeonjeong Chu, Hyejin Kim, Eunha Kim, Sanghee Lee · 2023 · Biomedicine & Pharmacotherapy
49. Pleural Mesothelioma: Treatable Traits of a Heterogeneous Disease
    Francesco Rocco Bertuccio, Francesco Agustoni, Giulia Galli, Chandra Bortolotto, Jessica Saddi, Guido Baietto, Nicola Baio, Simone Montini, Paola Putignano, Gioacchino D’Ambrosio et al. · 2023 · Cancers
50. Hierarchical cluster analysis and nonlinear mixed-effects modelling for candidate biomarker detection in preclinical models of cancer.
    David Hodson, Hitesh B. Mistry, James W.T. Yates, Sofia Guzzetti, Michael Davies, Leon J Aarons, Kayode Ogungbenro · 2024 · European Journal of Pharmaceutical Sciences
51. An updated patent review of stimulator of interferon genes agonists (2021 – present)
    Guo-Feng Xin, Nannan Chen, Lin-Lin Li, Xuechun Liu, Chun-Chen Che, Bei-Duo Wu, Qidong You, Xiaoli Xu · 2024 · Expert Opinion on Therapeutic Patents
52. 10th anniversary of discovering cGAMP: synthesis and beyond
    Chuo Chen · 2023 · Organic Chemistry Frontiers
53. Repurposing Infectious Pathogen Vaccines in Cancer Immunotherapy
    Matteo Conti · 2020 · IntechOpen eBooks
54. Toxicity of extracellular cGAMP and its analogs to T cells is due to SLC7A1-mediated import
    Valentino Sudaryo, Dayanne R. Carvalho, J. Michelle Lee, Jacqueline A. Carozza, Xujun Cao, Anthony F. Cordova, Lingyin Li · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
55. Recent Advances in Prodrug‐Loaded Nanoparticles for Enhanced Immunotherapy Efficacy
    Yajun Xu, Jincheng Du, Ya Liu, Chuwen Luo, Zhaohui Tang, Xuesi Chen · 2025 · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology
56. A multidomain peptide hydrogel-liposome composite for controlled release of a cyclic dinucleotide in oral cancer
    Joseph W. R. Swain, Andrea H Molina, Gemalene M. Sunga, Danielle Chew-Martinez, Neeraja Dharmaraj, Alejandra Cobos Perez, Arghadip Dey, Ephraim J. Vázquez-Rosado, Simon Young, Jeffrey D. Hartgerink · 2026 · Journal of Controlled Release
57. cGAS-STING Signalling in the tumour microenvironment: Implications for immune surveillance and therapeutic strategies
    Teeb Yasir Mahmoud Al-Adayleh, Waqas Ahmad, Siti Sarah Fazalul Rahiman, Vikneswaran Murugaiyah, Rafeezul Mohamed, Sheryar Afzal, Rahmeh Saad Al-Ramamneh, Ali Attiq · 2026 · International Immunopharmacology
58. Development in the Study of Natural Killer Cells for Malignant Peritoneal Mesothelioma Treatment
    Y Liu, He‐Liang Wu, Yan‐Dong Su, Yi Wang, Yan Li · 2024 · Cancer Biotherapy and Radiopharmaceuticals
59. Reovirus combined with a STING agonist enhances anti-tumor immunity in a mouse model of colorectal cancer
    Eiji Kubota, Naomi Sugimura, Yoshinori Mori, Mineyoshi Aoyama, Mamoru Tanaka, Takaya Shimura, Satoshi Tanida, Randal N. Johnston, Hiromi Kataoka · 2022 · Research Square
60. Mining bone metastasis related key genes of prostate cancer from the STING pathway based on machine learning
    Guiqiang Li, Runhan Zhao, Zhou Xie, Xiao Qu, Yingtao Duan, Yafei Zhu, Hao Liang, Dagang Tang, Zefang Li, Weiyang He · 2024 · Frontiers in Medicine
61. Orally bioavailable STING antagonist synthesized via multi-component Povarov–Doebner type reaction
    Kofi B. Owusu, Jyotrimayee Samal, Delmis E. Hernandez, Herman O. Sintim · 2024 · Chemical Communications
62. AlbiCDN: albumin-binding amphiphilic STING agonists augment the immune activity for cancer immunotherapy
    Shao‐Hua Zhuo, Xi Chen, Lang Zhao, Tianyang Wang, Jingyun Su, Tao Yang, Lijun Yang, Fei Dong, Yufen Zhao, Yanmei Li · 2025 · RSC Medicinal Chemistry
63. Carriers Multimerize STING Protein Fragments to Activate Type I Interferon Signaling in STING-Deficient Cancer Cells
    Justin A. Kaskow, Paula Therese Hammond · 2025 · Molecular Pharmaceutics
64. Phosphatidylserine blockade by dipicolylamine-zinc enhances chemoimmunotherapy of B16F10 melanoma
    Jianping Wang, Fanfei Meng, Ziang Chen, Yanying He, Jung Suk Kim, Karen Gutierrez Parra, Kunyu Jiang, Trevor G. Sargent, Yoon Yeo · 2025 · Journal of Pharmaceutical Sciences
65. A protective cGAMP-mediated anti-tumor immune response can proceed without LRRC8/VRAC channels
    Fabian M.B. Thöne, Maya M. Polovitskaya, Uta E. Höpken, Armin Rehm, Thomas J. Jentsch · 2025 · Journal of Biological Chemistry
66. Nanoengineering of STING-IDO1 feedback machinery potentiates antitumor immunity
    Yanming Xia, Lixin Hu, Xiaohu Wang, Mingxi Li, Bo Shi, Siqi Zhu, Yutong Wu, Shuting Xiang, Lifang Yin, Suxin Li · 2026 · Chemical Engineering Journal
67. Application of injectable hydrogels in immunotherapy via the cGAS-STING pathway for cancer and inflammatory disease treatment
    Yangyun Ge, Bowei Xiang, Jiamin Chen, Zongyu Guan, Jian Gong, Yi Su, Kaikai Wang · 2026 · Materials Today Advances
68. Nano‐Enabled Systemic Delivery of STING Agonist by Engineered Silicasome for Potent Antitumor Immunotherapy
    Wenjing Zhou, Yiming Li, Xudong Sun, Honghong Yang, Xiayu Shi, Lijia Yao, Jinhong Jiang, Erli Wang, Hao Wang, Yi Wei et al. · 2026 · Advanced Science
69. A copper-engineered MnO₂ nanoplatform for potentiating STING activation and antitumor immunity in colorectal cancer
    Jing Sun, Zhenxiong Zhao, Yunze Li, Xiaofang Wang, Jia Li, Zhe Huang, Hao Xu · 2026 · Colloids and Surfaces B Biointerfaces
70. A BCG hydrogel enables localized NOD2/STING activation to overcome resistance to immune checkpoint blockade
    Ziyuan Xiao, Huizhen Xu, Ningyi Ma, Lei Lei, Chunyu Cong, Ningyi Sun, Guodong Wang, Xi Chen, Ke Ren, Haishi Qiao · 2026 · Proceedings of the National Academy of Sciences
71. STING Activation in Dendritic Cells Enhances Antigen Presentation by Live Tumor Cells
    Adriana Loverre, Bakhos Jneid, Magali Genest, Maries F. van den Broek, Nicolas Manel · 2026 · European Journal of Immunology
72. Targeting tumor-specific T cells with LAG3-directed interleukin-2 prevents T-cell exhaustion and reinvigorates antitumor immunity
    Xiaohong Yu, Huiping Liao, Jiaoyun Lv, Yu Sun, Ruiqi Zhang, Yiwei Chen, Yifan Lin, Lulu Liu, Shijie Li, Hui Tang et al. · 2026 · Signal Transduction and Targeted Therapy
73. An Engineered Nano‐Bridging Strategy Remodels the Immune Microenvironment of Esophageal Squamous Cell Carcinoma via STING Pathway Activation
    Chaofan Huang, Xin Tang, Yixiao Zhao, Dafu Xu, Congyong Sun, Chenlong Wang, Fei Xie, Fangyi Xu, Chao Luo, Li Zhang et al. · 2026 · MedComm
74. Bridging DNA damage and cGAS-STING activation: Platinum (IV) prodrugs as single-molecule chemo-immunotherapeutics
    Junkang Ren, Jiani Wu, Xinyu Dai, Feihong Chen · 2026 · European Journal of Medicinal Chemistry
75. Role of cGAS-STING signaling pathway in colon cancer
    Siwei Wang, Wen-Hao Su, Xuemei Jia, Haotian Jiang, Binglu Huang, Weiguo Dong · 2020 · World Chinese Journal of Digestology
76. Discovery and Chemical Development of Uvelostinag (MK-1454): A Therapeutic Cyclic Dinucleotide Agonist of the Stimulator of Interferon Gene
    Matthew L. Maddess, John A. McIntosh, Wonsuk Chang · 2022 · ACS symposium series
77. Polio virotherapy provokes MDA5 signaling and CD4 + T cell help to mediate cancer in situ vaccination
    Matthias Gromeier, Michael C. Brown · 2025 · Microbiology and Molecular Biology Reviews
78. Intratumoral Manipulation of the Immune Microenvironment of Solid Tumors
    Lanyin Mao, Kexin Xu, Tianle Jin, Weiyi Yan, Ronnie H. Fang · 2025 · ACS Nano Medicine
79. Powerful synergistic effects of a STING agonist and an IL-2 superkine in cancer immunotherapy against MHC I-deficient and MHC I+ tumors
    Natalie K. Wolf, Cristina Blaj, Lora K. Picton, Gail Snyder, Li Zhang, Christopher J. Nicolai, Chudi O. Ndubaku, Sarah M. McWhirter, K. Christopher García, David H. Raulet · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
80. The crosstalk between DNA-PK and cGAS drives tumor immunogenicity
    Clara Taffoni, Johanna Marines, Hanane Chamma, Mathilde Saccas, Amel Bouzid, Soumyabrata Guha, Ana Luiza Chaves Valadão, Katarzyna Polak, Maguy Del Rio, Céline Gongora et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
81. CYCLIC DINUCLEOTIDES
    Zhenghua Wang, Dejun Ma, Zhen Xi · 2022 · Wiley eBooks
82. cGAS/STING and NLRP3 cooperatively activate CD8+ T cell-mediated anti-tumor immunity in colorectal cancer
    Courtney Mowat, Daniel Schiller, Kristi Baker · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
83. Constitutive cGAS-STING activation in ALT+ cells
    Dan Geelen, Alexander Beacom, Mélina Vaurs, Manon Mahieu, Rachid Boutoual, Amélie Derumier, Remington E. Hoerr, Axelle E. Loriot, Joe Nassour, Anabelle Decottignies · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
84. ENPP1 inhibitor with ultralong drug-target residence time as an innate immune checkpoint blockade cancer therapy
    Randolph M. Johnson, Songnan Wang, Jacqueline A. Carozza, Daniel Fernández, Jan J. Scicinski, Neil A. Verity, Rachel E. Mardjuki, Xujun Cao, Jacqueline S. Papkoff, Nigel Ray et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
85. The contribution of Sting and Nlrp3 activation to anti-tumour immunity in microsatellite instable colorectal cancer
    Courtney Mowat · 2019 · ERA: Education and Research Archive (University of Alberta)
86. Mechanisms of Clearance of MHC I-deficient Tumors Induced by STING Agonists
    Christopher J. Nicolai · 2020 · eScholarship (California Digital Library)
87. The Microbiome and Urologic Cancers
    Mithunah Krishnamoorthy, Saman Maleki Vareki, Jeremy P. Burton · 2021 · Physiology in health and disease
88. STING Agonist Enhances the Efficacy of PD-L1 Monoclonal Antibody in Breast Cancer Immunotherapy by Activating the IFNβ Signaling Pathway
    Mingming Yin, Jinlong Hu, Zhongxu Yuan, Guangyi Luo, Jiaming Yao, Rundong Wang, Dongquan Liu, Baoqiang Cao, Zhiqi Hu, Wenyong Wu · 2021 · Research Square
89. Identification and Characterization of Small-Molecule IRF3-Dependent Immune Activators for Pharmaceutical Development
    Marie H. Foss, Susan L. Stevens, Haihong Jin, Elyse M. Allen, Dylan Nelson, Victor R. DeFilippis, Aaron Nilsen, Mary P. Stenzel‐Poore · 2022 · ACS Chemical Biology
90. Biological Sensors for Microbiome Diagnostics
    Amy M. Ehrenworth Breedon, Kathryn Beabout, Heidi G. Coia, Christina M. Davis, Svetlana V. Harbaugh, Camilla A. Mauzy, Mark Nelson, Roland Saldanha, Blake W. Stamps, Michael S. Goodson · 2022
91. Faculty Opinions recommendation of SLC19A1 Is an Importer of the Immunotransmitter cGAMP.
    Bryan R.G. Williams, Michael Paul Gantier · 2019 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
92. Neuartige Poxin‐stabile cGAMP‐Derivate als bemerkenswerte STING‐Agonisten
    Samuele Stazzoni, Daniel F. R. Böhmer, Fabian Hernichel, Dilara Özdemir, Aikaterini Pappa, David Drexler, Stefan Bauernfried, Gregor Witte, Mirko Wagner, Simon Veth et al. · 2022 · Angewandte Chemie
93. Targeted delivery of low-dose liposomal STING agonist to CD103+ dendritic cells in tumor immunotherapy
    Aatman S. Doshi · 2021
94. STING signaling modulates CD8 T cell memory fitness via differential TCR signaling
    Michael J. Quaney · 2022
95. 1156 STING activation in sarcoma: assessing translational therapeutic strategies
    Karys M. Hildebrand, Kurt Hildebrand, Kayla Marritt, Carolina Salazar Arcila, Michael J. Monument · 2022 · Regular and Young Investigator Award Abstracts
96. Type I Interferon Signaling on Antigen-Presenting Cells Blunts Cell-Mediated Immunity Toward Listeria monocytogenes
    Zachary T. Morrow, John‐Demian Sauer · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
97. Identification of an Eight-Cuproptosis-related lncRNA Signature as a Novel Prognostic Model and Prediction of Immunotherapy Response in Ovarian Cancer
    Dan Sun, Shanshan Lin, Huayi Qin, Ying Yang, Junru Tong, Zhifu Zhi, Jiangtao Fan · 2023 · Research Square
98. Synthetic STING agonists elicit powerful vaccine adjuvancy providing robust central memory and anti-tumour effects
    Laurence D. Towner, Lekh N. Dahal, Martin C. Taylor, Kerry L. Cox, Tatyana Inzhelevskaya, Matthias Mack, Stephen R. Wedge, Caroline J. Richardson, Mark Steven Cragg, Stephen A. Beers · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
99. A via de sinalização de STING limita o potencial patogênico de células TH17
    Luis Eduardo Alves Damasceno · 2023
100. Bioorthogonal Imaging Probe for Sting Protein in Live Cell and Fixed Tissue
     Eunha Kim, Hye Lim Lee, Ju‐Young Park, Jubeen Yoon, Wonjin Park, G. Kate Park, Minseob Koh, Chang Ho Sohn, Sanghee Lee · 2023 · SSRN Electronic Journal